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Previvors are individuals who have a much greater
predisposition to cancer than individuals in the general
population but who have not yet developed the disease. This
group comprises individuals with deleterious mutations,
family histories of cancer, and other high-risk factors for
cancer (1). Preventive strategies targeting previvors corre-
spond to the earliest measure of cancer prevention (2,3).
Interventions addressed to previvors are more efficient in the
sense that a greater benefit can be observed per individual
receiving the intervention (2). Ovarian cancer is the most
lethal of all gynecological malignancies, and screening
programs do not significantly decrease mortality from this
disease, although previvors can currently be well identified
(4-7). Women with germline pathogenic mutations of the
BRCA1 and/or BRCA2 genes have a lifetime risk of ovarian
cancer development that ranges from 20% to 65% (8-10). For
these ovarian cancer previvors, the concept of taking action
to avoid cancer is incipient, and well-structured strategies
and programs are lacking (11,12).
The origin of precursor lesions and ovarian cancer
High-grade serous ovarian carcinoma (HGSC), the most
frequent and aggressive histological type of ovarian cancer,
originates in fimbrial cells that are secondarily implanted
in the ovary (13). This type of carcinoma can start in the
fallopian tubes and implant and grow in the ovary at an
early stage, or it can originate in normal tubal cells implanted
in the ovulatory wound during ovulation (13). The origin of
cancer depends on local factors and/or host fragility (14,15).
Women with mutations in the BRCA genes carry conditions
that favor the development of HGSC in the tubal epithelium
(15). It is therefore reasonable to consider that efforts to
prevent ovarian cancer should focus on intervention in the
fimbriae to prevent cell implantation in the ovaries, and thus,
cancer development.
Factors that prevent fimbrial cell implantation in the ovary,
such as the prolonged use of anovulatory contraceptives and
salpingectomy for any reason, have been shown to sig-
nificantly reduce the incidence of ovarian cancer (16,17).
The implantation of fimbrial cells in the ovary begins with
the onset of ovulation. The amount of ovulation occurring
over a woman’s lifetime is closely related to the incidence
rate of ovarian cancer (18,19). It is reasonable to suppose that
earlier interruptions of fimbrial cell implantation will have a
greater benefit in the prevention of ovarian cancer.
Precursor lesions and early serous carcinoma were first
identified in specimens from prophylactic salpingo-oophor-
ectomies performed in high-risk patients (20,21). Examples of
these precursors, which precede the onset of invasive ovarian
cancer by several years, are the p53 protein signature, atypia
in hyperplasic epithelium, and serous tubal intraepithelial
carcinoma (STIC) (21) (Figure 1). Precursor cancer is a defi-
nable pathological state that progresses to cancer and can be
targeted to prevent cancer progression (2). The HGSC precur-
sor, termed the p53 signature, precedes invasive ovarian
carcinoma by decades, and STIC precedes carcinoma by at
least 6 years (21-23). Therefore, acting on these precursors
seems to be a good strategy to prevent HGSC, but this
strategy should be implemented before the age at which
prophylactic surgery has to been performed.
Ovarian cancer in previvors in the genetic
testing era
Many factors have contributed to the increased identifica-
tion of ovarian cancer previvors, including a) the advent and
popularization of genetic testing, b) increased interest in the
identification of ovarian carcinoma survivors with patho-
genic mutations who are candidates for targeted therapy
with poly(ADP-ribose) polymerase (PARP) inhibitors, and c)
the identification of the relatives of these patients who also
carry pathogenic mutations (24-26). The major question is,
what measures should we take with these ovarian cancer
previvors beyond the recommended prophylactic salpingo-
oophorectomy, which has undesirable consequences?
Prophylactic salpingo-oophorectomy is currently recom-
mended for women with deleterious BRCA1 mutations at
35-40 years of age (or at any time after childbearing is
completed). For those with deleterious BRCA2 mutations,
this surgery is recommended at 40-45 years of age (27,28).
However, the performance of prophylactic surgery at the
recommended age confers protection in approximately 80-90%
of cases (29-31). In addition, a considerable number of women
already present with occult lesions at the time of surgery, and
the disease may develop in the peritoneum. Hidden serousDOI: 10.6061/clinics/2019/e1343
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carcinoma or STIC has been detected in 1-17% of surgical
specimens obtained during such surgeries (32,33).
In a prospective study that followed 5,783 women with
a BRCA1 or BRCA2 mutation for 5.6 years, 186 ovarian,
fallopian, and peritoneal cancers were observed in addition
to the 46 occult cancers observed at the time of salpingo-
oophorectomy and the 32 peritoneal cancers observed after
oophorectomy (34). In this study, the specimens from the risk
reduction surgeries performed in the patients with deleter-
ious BRCA1 mutations, the detection frequency of occult
carcinoma varied with age (1.5% at o40 years old, 3.8% at
40-49 years old, and over 7% at450 years old, reaching 12%
at 60-64 years old) (34). The occurrence rate of peritoneal
carcinoma after salpingo-oophorectomy in patients with
deleterious BRCA1/BRCA2 mutations ranged from 0.8% to
1.8% (30,35-37). Moreover, most women do not undergo
prophylactic salpingo-oophorectomy at the recommended
age; approximately only 17% undergo surgery before the age
of 40 years old (38).
Prophylactic salpingo-oophorectomy has a great impact
on women’s quality of life, as it results in premature meno-
pause, vasomotor symptoms, sexual dysfunction, cardiovas-
cular disease, osteoporosis, cognitive deficits, and an
increased risk of premature death (39-46). These undesired
effects are the main barriers to patients’ adherence to these
prophylactic procedures, even in the face of the great risk
of ovarian cancer (47,48).
Prophylactic salpingectomy with delayed
oophorectomy
An alternative to prophylactic salpingo-oophorectomy,
which does not result in early menopause, is prophylactic
salpingectomy with delayed oophorectomy. The theoretical
benefit of this procedure is based on the expectation that early
removal of the fallopian tubes prevents the implantation of
fimbrial cells in the ovulatory wound. Thus, early salpingect-
omy provides greater protection than late salpingectomy.
Bilateral salpingectomy with delayed oophorectomy is less
damaging to women than salpingo-oophorectomy; conse-
quently, this procedure has a greater the chance to be accep-
ted by women (9,49-53). A prospective, nonrandomized,
pilot study with 43 premenopausal patients with a BRCA
mutation was conducted, and 19 (44%) patients chose sal-
pingectomy with delayed oophorectomy, 12 (28%) patients
chose salpingo-oophorectomy, and 12 (28%) patients chose
to be screened only (52). The patients who underwent
salpingectomy were satisfied with their choice and had
decreased worry and anxiety about cancer after the surgery.
In a qualitative study performed with 39 BRCA1/2 mutation
carriers and 23 health professionals using explorative inter-
views, the maintenance of ovarian function with the delay
of the negative effects of early menopause and infertility was
considered a facilitator influencing the choice to undergo
salpingectomy with delayed oophorectomy instead of sal-
pingo-oophorectomy by both patients and treating profes-
sionals (50). On the other hand, the seriousness of ovarian
cancer and the lack of strong evidence for the new strategy
worries professionals and patients (50,51). However, although
there are no large prospective randomized studies indicating
increased safety and a reduced risk of ovarian cancer with
salpingectomy compared to the safety and risk with oophor-
ectomy, we have some promising evidence supporting this
concept. A simulation model was developed to estimate the
costs and benefits of the following three risk-reducing
strategies in BRCA mutation carriers: bilateral salpingo-
oophorectomy at 40 years old, bilateral salpingectomy at
40 years old, and bilateral salpingectomy at 40 years old
followed by bilateral oophorectomy at 50 years old (54).
Although bilateral salpingo-oophorectomy was associated with
the greatest risk reduction for ovarian cancer, when quality
of life was included in the model, bilateral salpingectomy with
delayed oophorectomy proved to be an acceptable alternative
for those unwilling to undergo the first procedure (54).
The proportion of patients who choose delayed oophor-
ectomy suggests that patient accrual for a clinical trial of
prophylactic salpingectomy with delayed oophorectomy is
possible.
Preimplantation genetic diagnosis (PGD)
Women with pathogenic mutations related to ovarian
cancer have a high risk of developing ovarian cancer and
may also transmit these mutations to their offspring. Current
genetic testing enables the identification of pathogenic germ-
line mutations in women of any age and in embryos.
Figure 1 - Spectrum of tubal fimbrial lesions. (A) Epithelial cells expressing p53 (p53 signature), (B) hyperplastic tubal epithelium with
atypia, (C) and (D) STIC.
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Preimplantation genetic diagnosis (PGD) is considered to
be an acceptable intervention to prevent the transmission
of deleterious genetic conditions to the next generation,
although much ethical controversy surrounds the considera-
tion of which deleterious conditions should be deemed
serious enough to justify such an intervention (55-57). PGD
decisions are complex, as reflected in a study conducted in
Israel with 70 women with deleterious BRCA1/2 mutations,
for whom the possibility of preventing the transmission of
these mutations through PGD and IVF was offered at no cost.
Only 25.7% of patients accepted the proposal, and acceptance
had no relationship to age or religious beliefs (58).
The combined performance of early prophylactic salpin-
gectomy, oocyte uptake, IVF, and, when acceptable, PGD,
would have many advantages over oophorectomy, at least
from a theoretical point of view. First, it would not only
preserve ovarian function but also enable pregnancy with
oocyte uptake and IVF. The need for IVF, in turn, presents a
great opportunity for PGD. Considering that precursors (the
p53 signature and STIC) predate ovarian cancer by decades
or years, this strategy could provide an opportunity for early
intervention. Moreover, salpingectomy could even be per-
formed in young women with pathogenic mutations before
they first ovulate. This strategy, combined with oocyte
uptake, IVF, and PGD, would allow the implantation of
healthy embryos in mothers at a reduced risk of ovarian
cancer while preventing infertility due to premature ovarian
failure and/or early menopause (59,60). Women adhering to
this strategy would have more time for oocyte capture and
the growth of healthy embryos for future implantation than
would those expecting through natural pregnancies.
Consequences of the proposal and discussion
When considered alone, many concepts, such as prophy-
lactic salpingo-oophorectomy, prophylactic salpingectomy
with delayed oophorectomy, oocyte uptake, IVF, PGD, ovar-
ian failure, and premature menopause, may be difficult for
laypeople to understand. A strategy combining all of these
concepts, named ‘‘the maximal effort to prevent ovarian
cancer while preserving the ovaries,’’ should be proposed to
high-risk patients and might be better accepted by a large
number of women.
This strategy could be tested in a randomized, global
study that addresses all aspects of this complex issue from
the perspectives of oncology, human reproduction, genetics,
legality, medical ethics, and relevant educational, cultural,
psychosocial, and religious aspects.
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